Viking Therapeutics
9920 Pacific Heights Blvd, Suite 350
San Diego
California
92121
United States
Tel: 858-550-7810
Website: http://www.vikingtherapeutics.com/
Email: info@vikingtheraputics.com
218 articles about Viking Therapeutics
-
Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting
7/17/2018
Presentation to Highlight Data for Novel, Orally Available SARM in Patients Recovering from Hip Fracture Surgery
-
Viking Therapeutics Announces Closing of Public Offering of 8,625,000 Shares of Common Stock
6/12/2018
Viking Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock
-
Viking Therapeutics Announces Pricing of $67.5 Million Public Offering of Common Stock
6/7/2018
Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $67.5 million.
-
Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors
6/7/2018
Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors.
-
Viking Therapeutics Announces Proposed Public Offering of Common Stock June 6, 2018
6/6/2018
Viking Therapeutics, Inc. announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
-
Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
6/5/2018
Top-Line Results Expected in Second Half of 2018
-
Viking Therapeutics to Report Financial Results for First Quarter 2018 on May 9, 2018
5/2/2018
Viking Therapeutics, Inc. announced that the company will release financial results for the first quarter of 2018 after the market close on Wednesday, May 9, 2018.
-
Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
3/7/2018
Viking Therapeutics Inc. announced its financial results for the fourth quarter and year ended December 31, 2017, and provided an update on its clinical pipeline and other corporate developments.
-
Viking Announces Closing of Public Offering of Common Stock
2/7/2018
The gross proceeds to Viking from this offering are approximately $63.3M, before deducting underwriting discounts and commissions and other estimated offering expenses.
-
Viking Therapeutics Announces Pricing of $55M Public Offering of Common Stock
2/2/2018
In addition, Viking has granted the underwriters a 30-day option to purchase up to 1,650,000 additional shares of its common stock.
-
Viking Announces Proposed Public Offering of Common Stock
2/2/2018
Viking today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
-
Top 6 Biotech Stocks of 2017
12/20/2017
When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates. -
Viking Therapeutics Announces Closing of Public Offering of Common Stock
12/12/2017
The gross proceeds to Viking from this offering are approximately $14.8M, before deducting underwriting discounts and commissions and other estimated offering expenses.
-
Viking Therapeutics Announces Pricing of $12.8 Million Public Offering of Common Stock
12/7/2017
Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $12.8M.
-
Viking Therapeutics Announces Proposed Public Offering of Common Stock
12/6/2017
All of the shares to be sold in the offering are to be sold by Viking.
-
Viking Therapeutics Announces Positive Top-Line Results From Phase II Study of VK5211 in Patients Recovering From Hip Fracture
11/28/2017
Top-line data showed that the trial achieved its primary endpoint, demonstrating statistically significant, dose dependent increases in lean body mass, less head, following treatment with VK5211 as compared to placebo.
-
Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
11/8/2017
Research and development expenses for the three months ended September 30, 2017 were $3.5 million compared to $2.1 million for the same period in 2016.
-
Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017
11/1/2017
Brian Lian, Ph.D., Viking's president and CEO, and Michael Morneau, Viking's CFO, will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, November 8, 2017.
-
Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed NASH at the Annual Meeting of the AASLD
10/24/2017
Viking today announced positive final results from an eight-week study of VK2809 in an in vivo model of NASH.
-
Viking Therapeutics Presents Results From Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association
10/23/2017
Viking today announced positive results from a 25-week proof-of-concept study of VK0214 in an in vivo model of X-linked adrenoleukodystrophy (X-ALD).